Turnbridge Capital

Founded in 2008 and headquartered in Dallas, Texas with an additional office in Houston, Turnbridge Capital is a private equity firm specializing in management buyouts, corporate spinouts, leveraged build-ups, strategic growth capital infusions, and shareholder recapitalizations. The firm primarily invests in middle market companies across various industries, including energy and infrastructure, industrial manufacturing and services, and transportation and distribution, with a focus on the southwest region of the United States. Turnbridge Capital seeks to invest between $10 million and $75 million in companies with enterprise values ranging from $50 million to $250 million, typically holding investments for three to seven years while seeking majority ownership.

C. Chris Martin

CFO and CCO

J. Kent Sweezey

Partner

3 past transactions

Gradiant Energy Services

Venture Round in 2017
Gradiant Energy Services, Inc. is an oilfield services company focused on addressing the water challenges faced by the oil and gas industry. Founded in 2012 and headquartered in Denver, Colorado, with a regional office in Midland, Texas, the company offers a range of water treatment solutions, including bacteria treatment, reusable clean brine, evaporative disposal, and freshwater/desalination and brine collection. Gradiant Energy Services caters to oil and gas exploration and production operators who require effective treatment, reuse, and recycling of flowback and produced water. The company's custom-engineered solutions and innovative technologies aim to provide safe, reliable, and environmentally efficient services to its clients in the Permian and Marcellus shale plays.

Cimarron Energy

Acquisition in 2014
Founded in the early 1980s, Cimarron Energy specializes in engineering and manufacturing emissions control solutions for various industries. The company offers products such as vapor recovery units and combustors to manage and mitigate greenhouse gas emissions. Additionally, they provide compliance services and maintain safety plans through membership with ISNetworld.

Morphotek

Series B in 2001
Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.